Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of FSK1924-2 vs Revlimid
jRCT2031210413Completed
- Sponsor
- Fuji Pharma Co., Ltd.
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of lenalidomide in multiple myeloma (MM) and 5q deletion syndrome (2 arms), sponsored by Fuji Pharma Co., Ltd. Primary endpoints: AUCt and Cmax. Started Nov 2021; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)5q deletion syndrome
Beyond the preview
Go deeper on jRCT2031210413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210413.